SAM
VERV

Shell Asset Management’s Verve Therapeutics VERV Stock Holding History

Shell Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,806
Closed -$65K – 1265
2025
Q2 		$65K Hold
5,806
– – ﹤0.01% 1101
2025
Q1 		$27K Sell
5,806
-229
-4% -$1.53K ﹤0.01% 1212
2024
Q4 		$34K Hold
6,035
– – ﹤0.01% 1215
2024
Q3 		$29K Buy
+6,035
New +$35.1K ﹤0.01% 1217
2024
Q1 		$28K Sell
5,769
-647
-10% -$8.58K ﹤0.01% 1210
2023
Q4 		$89K Buy
+6,416
New +$79.5K ﹤0.01% 1093

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Shell Asset Management's VERV Position: Q3 2025 in Review

Shell Asset Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 5,806 shares — an estimated $65K sold.

Shell Asset Management first reported a position in VERV in Q4 2023 and held it in 6 quarters. The position peaked at $89K in Q4 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Shell Asset Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Shell Asset Management sold 5,806 Verve Therapeutics shares in Q3 2025, an estimated $65K.
  • Shell Asset Management first reported a position in Verve Therapeutics in Q4 2023 and held it in 6 quarters.
  • Shell Asset Management's Verve Therapeutics position peaked at $89K in Q4 2023.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.